Skip to main content
TipRanks
Go Ultimate75% OFF

Omkar Speciality Chemicals Limited (OMKARCHEM) AI Stock Analysis

0 Followers
IN:OMKARCHEM

Omkar Speciality Chemicals Limited

(NSE:OMKARCHEM)

Select Model
Rating:42Neutral
Price Target:INR 3.50â–¼(-2.78% Downside)
Action:initiatedcoverage
Date:09/24/26

Severely weak financial performance with revenue collapse and negative cash flows is the dominant factor, compounded by unattractive valuation from losses and weak technical momentum below key averages.

Positive Factors
FY2026 Balance-Sheet ImprovementThe return to positive equity and substantially lower reported debt improves financial flexibility compared with the prior period of negative equity. If maintained, this provides a stronger capital base for stabilisation, although the improvement has not yet translated into operating recovery.
Negative Factors
Extreme Revenue ContractionThe collapse in revenue indicates a severe loss of operating scale and materially weakens the company’s ability to absorb fixed costs. Rebuilding a dependable customer and revenue base would be necessary before profitability, cash generation, or competitive position can become durable.

Omkar Speciality Chemicals Limited (OMKARCHEM) vs. iShares MSCI India ETF (INDA)

-40%-30%-20%-10%0%10%20%IN:OMKARCHEM-32.08%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 70.17M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-4.5
Beta (1Y)
0.37
Revenue Growth
―
EPS Growth
―
Country
India
Employees
59
Sector
General
Sector Strength
55
Industry
Chemicals - Specialty

Omkar Speciality Chemicals Limited Business Overview & Revenue Model

Company Description

Omkar Speciality Chemicals Limited (OSCL) is a prominent manufacturer and global supplier of specialized chemicals and intermediates, catering to a wide array of chemical and allied sectors both domestically in India and across international markets....

Omkar Speciality Chemicals Limited Financial Statement Overview

Summary

Revenue has collapsed with persistent negative margins and recent negative cash flows, though the balance sheet shows improvement via positive equity and low debt.

Income Statement

18Very Negative

Balance Sheet

48Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue82.00K82.00K2.24M229.82M229.82M451.25M
Gross Profit-4.43M-9.09M-9.07M62.82M62.82M118.89M
EBITDA-3.22M-8.55M-3.97M-47.46M-47.46M122.75M
Net Income-6.93M-15.89M-13.04M-126.05M-126.05M20.14M
Balance Sheet
Total Assets0456.49M480.38M721.72M721.72M863.63M
Cash, Cash Equivalents and Short-Term Investments26.48M26.48M44.52M103.46M3.33M1.67M
Total Debt031.05M3.82B2.26B2.26B2.28B
Total Liabilities-187.25M269.24M4.05B2.43B2.43B2.45B
Stockholders Equity187.25M187.25M-3.57B-1.71B-1.71B-1.58B
Cash Flow
Free Cash Flow0-16.68M9.06M8.92M8.92M-164.30M
Operating Cash Flow0-14.66M9.06M8.92M8.92M-164.12M
Investing Cash Flow0-2.89M1.11M1.75M1.75M173.49M
Financing Cash Flow0-487.00K0-10.36M-10.36M-10.80M

Omkar Speciality Chemicals Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price3.60

Price Trends

50DMA3.60Positive
100DMA3.60Negative
200DMA3.94Negative

Market Momentum

MACD-0.00Negative
RSI31.33Neutral
STOCH0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:OMKARCHEM, the sentiment is Negative. The current price of 3.60 is above the 20-day moving average (MA) of 3.60, above the 50-day MA of 3.60, and below the 200-day MA of 3.94, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 31.33 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:OMKARCHEM.

Omkar Speciality Chemicals Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:OMKARCHEM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:FCLIN:FCL69NeutralINR 61.86B44.31―0.24%91.44%19.67%
IN:ROSSARIIN:ROSSARI65NeutralINR 24.27B15.81―0.11%19.76%11.74%
IN:CHEMCONIN:CHEMCON61NeutralINR 7.42B24.80―3.20%22.25%20.33%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:LXCHEMIN:LXCHEM47NeutralINR 43.94B25.54―0.19%21.34%105.39%
IN:NEOGENIN:NEOGEN46NeutralINR 84.36B188.13―0.04%26.66%51.16%
IN:OMKARCHEMIN:OMKARCHEM42NeutralINR 74.08M-4.55――――

* General Sector Average

Performance Comparison

0%50%100%IN:OMKARCHEMIN:CHEMCONIN:FCLIN:LXCHEMIN:NEOGENIN:ROSSARIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:OMKARCHEM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:OMKARCHEMOmkar Speciality Chemicals Limited3.60-1.66-31.56%
IN:CHEMCONChemcon Speciality Chemicals Ltd202.65-20.61-9.23%
IN:FCLFineotex Chemical Limited53.1228.32114.16%
IN:LXCHEMLaxmi Organic Industries Ltd.158.10-28.58-15.31%
IN:NEOGENNeogen Chemicals Ltd.2808.051477.84111.10%
IN:ROSSARIRossari Biotech Ltd438.10-191.74-30.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 24, 2026